Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics

Biomarkers that predict therapeutic response are essential for the development of anticancer therapies. We have used matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) to directly analyze protein profiles in mouse mammary tumor virus/HER2 transgenic mouse frozen tumor sections after treatment with the erbB receptor inhibitors OSI-774 and Herceptin. Inhibition of tumor cell proliferation and induction of apoptosis and tumor reduction were predicted by a >80% reduction in thymosin β4 and ubiquitin levels that were detectable after 16 hours of a single drug dose before any evidence of in situ cellular activity. These effects were time- and dose-dependent, and their spatial distribution in the tumor correlated with that of the small-molecule inhibitor OSI-774. In addition, they predicted for therapeutic synergy of OSI-774 and Herceptin as well as for drug resistance. These results suggest that drug-induced early proteomic changes as measured by MALDI-MS can be used to predict the therapeutic response to established and novel therapies.

[1]  H. Kleinman,et al.  Role of Thymosin β4 in Tumor Metastasis and Angiogenesis , 2003 .

[2]  K. B. Pedersen,et al.  Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies , 2002, British Journal of Cancer.

[3]  L. Pustilnik,et al.  Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. , 1997, Cancer research.

[4]  H. Koeppen,et al.  HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice , 2004, Clinical Cancer Research.

[5]  M. Stoeckli,et al.  Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues , 2001, Nature Medicine.

[6]  Dana M. Brantley-Sieders,et al.  Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1 , 2003, Molecular and Cellular Biology.

[7]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Powles,et al.  Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer , 2003, Breast Cancer Research and Treatment.

[9]  C K Osborne,et al.  Selective estrogen receptor modulators: structure, function, and clinical use. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Arteaga,et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .

[11]  P. Chaurand,et al.  Profiling proteins from azoxymethane‐induced colon tumors at the molecular level by matrix‐assisted laser desorption/ionization mass spectrometry , 2001, Proteomics.

[12]  C. Arteaga.  Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer , 2003, Breast Cancer Research.

[13]  Walter A. Korfmacher,et al.  Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. , 2003, Journal of mass spectrometry : JMS.

[14]  R. Bianco,et al.  Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.

[15]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[16]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Green.  Faculty Opinions recommendation of Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. , 2002 .

[18]  Baogang J. Xu,et al.  Profiling and imaging proteins in the mouse epididymis by imaging mass spectrometry , 2003, Proteomics.

[19]  A. Lenferink,et al.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Børresen-Dale,et al.  E‐cadherin and α‐, β‐, and γ‐catenin protein expression in relation to metastasis in human breast carcinoma , 1998 .

[21]  W. Birchmeier,et al.  Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex , 2002, Nature Cell Biology.

[22]  M. Stoeckli,et al.  Automated mass spectrometry imaging with a matrix-assisted laser desorption ionization time-of-flight instrument , 1999, Journal of the American Society for Mass Spectrometry.

[23]  A. Lenferink,et al.  ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. , 2001, Cancer research.

[24]  E K Rowinsky,et al.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Höfler,et al.  Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis. , 2003, Carcinogenesis.

[27]  Michelle L. Reyzer,et al.  Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation. , 2003, Journal of mass spectrometry : JMS.

[28]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[29]  M. Hochstrasser.  Ubiquitin-dependent protein degradation. , 1996, Annual review of genetics.

[30]  C. Arteaga,et al.  Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. , 2002, The Journal of clinical investigation.

[31]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[32]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.